Indications for SGLT2 Inhibitors in Adults with Type 2 Diabetes
Primary Glycemic Indication
- The American College of Physicians recommends adding SGLT2 inhibitors to metformin and lifestyle modifications when glycemic control is inadequate (typically HbA1c ≥7%) to reduce all-cause mortality, major adverse cardiovascular events, chronic kidney disease progression, and heart failure hospitalizations 1.
Priority Cardiovascular Indications
Heart Failure
- The American Heart Association recommends using SGLT2 inhibitors in all adults with type 2 diabetes and heart failure (either reduced or preserved ejection fraction) for both glycemic management and prevention of heart failure hospitalizations, regardless of current HbA1c level 2, 3, 4.
- This represents a Class I, Level A recommendation based on cardiovascular outcome trials demonstrating 26-29% reduction in cardiovascular death or heart failure hospitalization 1, 5.
Chronic Kidney Disease
- The National Kidney Foundation recommends initiating SGLT2 inhibitors in adults with type 2 diabetes and CKD (eGFR 20-60 mL/min/1.73 m² and/or albuminuria ≥200 mg/g) for glycemic management irrespective of HbA1c, and for slowing CKD progression, reducing cardiovascular events, and preventing heart failure hospitalizations 2, 3, 6.
- SGLT2 inhibitors reduce the composite renal outcome (sustained eGFR decline ≥50%, end-stage kidney disease, or renal death) by 44% 5.
- The American Diabetes Association prioritizes SGLT2 inhibitors as first-line add-on therapy in patients with CKD over other glucose-lowering agents 1, 7.
Additional Metabolic Indications
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
- Consider SGLT2 inhibitors (or GLP-1 receptor agonists) in adults with type 2 diabetes, MASLD, and overweight/obesity for glycemic management and as adjunctive therapy for weight loss 2, 3, 4.
Critical Renal Function Thresholds
- For glycemic control: Do not initiate SGLT2 inhibitors if eGFR <45 mL/min/1.73 m² as glucose-lowering efficacy is significantly reduced 6, 7, 5.
- For cardiovascular/renal protection: SGLT2 inhibitors can be initiated if eGFR ≥25 mL/min/1.73 m² (some guidelines support ≥20 mL/min/1.73 m²) 2, 3, 5.
Clinical Decision Algorithm
- Heart failure (any ejection fraction) → SGLT2 inhibitor mandatory 2, 3, 4.
- CKD with eGFR 20-60 mL/min/1.73 m² and/or albuminuria → SGLT2 inhibitor or GLP-1 RA 2, 3.
- Established cardiovascular disease → SGLT2 inhibitor strongly recommended 1.
Important Contraindications and Precautions
- Withhold SGLT2 inhibitors at least 3 days before major surgery or procedures with prolonged fasting to prevent euglycemic diabetic ketoacidosis 5.
- Temporarily discontinue during acute illness with reduced oral intake, fever, vomiting, or diarrhea 5.
- Monitor for genital mycotic infections (6% incidence vs 1% placebo) and urinary tract infections 1, 5.
- Assess volume status before initiation, especially in elderly patients (≥75 years), those on diuretics, or with low systolic blood pressure 5, 8.